Stay updated on Neo-Pembrolizumab + Androgen Blockade in Prostatectomy Clinical Trial

Sign up to get notified when there's something new on the Neo-Pembrolizumab + Androgen Blockade in Prostatectomy Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Neo-Pembrolizumab + Androgen Blockade in Prostatectomy Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    No Change Detected
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    6 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the dose of Pembrolizumab being administered in combination with intensive androgen receptor targeting prior to prostatectomy for high-risk localized prostate cancer.
    Difference
    0.1%
    Check dated 2024-06-06T14:36:22.000Z thumbnail image
  7. Check
    21 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to provide a more detailed explanation of eligibility criteria, including examples such as general health condition or prior treatments. Additionally, it now includes a link for general information about clinical research.
    Difference
    19%
    Check dated 2024-05-22T21:34:01.000Z thumbnail image
  8. Check
    43 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:34:50.000Z thumbnail image

Stay in the know with updates to Neo-Pembrolizumab + Androgen Blockade in Prostatectomy Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Neo-Pembrolizumab + Androgen Blockade in Prostatectomy Clinical Trial page.